Drug Profile

Anti-CD19 universal chimeric antigen receptor natural killer cell therapy - Chongqing Precision Biotech

Alternative Names: Anti-CD19 U-CAR-NK cell therapy - Chongqing Precision Biotech

Latest Information Update: 03 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Chongqing Precision Biotech Co., Ltd
Class Antineoplastics; CAR-NK cell therapies; Gene therapies; Immunotherapies
Mechanism of Action Immunologic cytotoxicity; Natural killer T cell replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

27 Nov 2022 Chongqing Precision Biotech withdraws a phase I/II trial in lymphoid leukaemia and B-cell lymphoma (Parentral) in China due to principal investigators decision (NCT05570188)
01 Oct 2022 Phase-I/II clinical trials in B-cell lymphoma in China (Parental) (NCT05570188)
01 Oct 2022 Phase-I/II clinical trials in Lymphoid leukaemia in China (Parental) (NCT05570188)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com